Allarity Therapeutics’ pipeline currently consists of six mid-to-late stage clinical candidates for cancer. The company is focused on the clinical development of three priority programs: Dovitinib, Stenoparib (2X-121), and Ixempra®. In addition, Allarity is supporting the development of three additional clinical assets through business development activitites. Each Allarity pipeline program is being co-developed with a drug specific DRP® companion diagnostic to select and treat patients most likely to benefit from treatment.
Allarity’s priority pipeline programs include:
- Dovitinib, a pan-tyrosine kinase inhibitor in development for renal cell carcinoma (RCC) as lead indication, and hepatic cell carcinoma, breast cancer, endometrial cancer and gastrointestinal stromal tumors as possible secondary indications.
- Stenoparib (2X-121), a dual PARP and Tankyrase Inhibitor in Phase 2 development for ovarian cancer
- IXEMPRA® (Ixabepilone), a microtubulin inhibitor in Phase 2 development for the European market for metastatic breast cancer
In addition, Allarity is supporting efforts to bring these other candidates through development:
- LiPlaCis®, a target controlled liposome formulation of one of the world’s most widely used chemotherapeutic agents, cisplatin. The specific LiPlaCis formulation allows delivery of LiPlaCis directly to the tumor site where is it needed. LiPlaCis had been out licensed to Smerud Medical Research International AS. Smerud will advance the specific development of LiPlaCis® in late stage metastatic breast cancer.
- 2X-111 (Glutathione-enhanced, PEGylated Liposomal Doxorubicin), novel drug candidate is designed for the liposomal delivery of the anti-cancer drug doxorubicin directly to a tumor, with a glutathione coating added to exploit active endogenous transporters, allowing the drug to cross the blood-brain barrier. Allarity has out-licensed 2X-111 to Smerud Research International AS to progress late stage clinical development for the potential treatment of glioblastoma multiform (GBM) (primary brain cancer) and potentially brain metastases of breast cancer (mBC).
- Irofulven, a synthetic drug candidate based on a naturally occurring substance that exploits a deficiency in the DNA repair mechanism of cancer cells in a manner similar to a PARP inhibitor. Allarity is running a single arm, open label Phase 2 Study of Irofulven for treatment of metastatic castration-resistant prostate cancer in patients who have previously been treated with docetaxel and who have been identified by the DRP® as having a high likelihood of response to Irofulven.